To that end, in early October, new data was presented at ASTRO 2024 the Annual Meeting of the American Society for Radiation ... was recently presented at the ESMO 2024 Congress in Barcelona ...
Dramatic advances in the understanding of basic molecular mechanisms of underlying ... branded medicines pricing and access. The European Society for Medical Oncology (ESMO) 2024 meeting was ...
The PCWG3 consensus guidelines have proven a robust set of imaging endpoints incorporated into ... @zklaassen_md on Twitter during the 2024 European Society of Medical Oncology (ESMO) Annual Meeting, ...
For the first time, researchers have observed how bromoform rearranges its atoms in less than a trillionth of a second after ...
PACT system combines the strengths of optical and ultrasound imaging, presenting a promising alternative to traditional imaging methods. Conventional whole-body PACT approaches, however, were ...
Executive Committee: Jukka Jernvall (Chair), Annette Becker, Carlos Guerrero Bosagna, Sylvie Rétaux, Rainer Melzer, Tom Van Dooren, Gerd Mueller Programme Committee: Sylvie Rétaux (Chair), Annette ...
The potential for technology to transform the way we deliver healthcare is nothing new. We’ve been discussing it for some years now and are starting to see more widespread adoption, particularly ...
At ESMO 2024, Bayer will present key results from the Phase III ARANOTE trial on NUBEQA® (darolutamide) for metastatic hormone-sensitive prostate cancer and the PEACE-III study of XOFIGO® (radium-223) ...
However, both pre-clinical and clinical studies have shown numerous applications of HA, low-molecular-weight (LMW) HA, and hybrid LMW/high-molecular-weight HA in dermatology. LMW-HA exhibits ...
Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.
Background: A standard treatment recommendation for third-line and subsequent treatments for advanced HER2-positive breast cancer is still missing, especially for low HER2 expression. Nevertheless, ...